Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03733353
Other study ID # EDP1815-101
Secondary ID 2018-002807-32
Status Completed
Phase Phase 1
First received
Last updated
Start date November 19, 2018
Est. completion date October 29, 2021

Study information

Verified date January 2022
Source Evelo Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evelo will investigate the safety and tolerability of EDP1815 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.


Description:

This will be a randomized, double-blind, placebo-controlled clinical study with dose escalations to assess safety, tolerability, and pharmacodynamic effect of EDP1815. Since this clinical study is the first study in humans, the participants will be healthy volunteers or subjects with mild to moderate psoriasis or atopic dermatitis who are otherwise well. Investigation of EDP1815 in this patient population provides an opportunity to gain pharmacodynamic information using a range of tissue biopsies and composite clinical endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 204
Est. completion date October 29, 2021
Est. primary completion date October 29, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: General: Participant has a body mass index of = 18 kg/m2 to = 35 kg/m2 at Screening. Healthy Volunteers: Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. Mild to moderate psoriasis: 1. Participant has had a confirmed diagnosis of mild to moderate plaque-type psoriasis for at least 6 months involving = 10% of body surface area (BSA) (excluding the scalp). 2. Participant has a minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for biopsy. Mild to moderate atopic dermatitis: 1. Mild to moderate atopic dermatitis with a minimum of 3% to a maximum of 15% BSA involvement. 2. Participant has had a confirmed diagnosis of mild to moderate atopic dermatitis for at least 6 months (IGA score of 2 or 3). 3. Participant has a minimum of 2 atopic dermatitis lesions with at least 1 in a site suitable for biopsy. Exclusion Criteria: 1. Female participant who is pregnant, or plans to become pregnant during the study, or breastfeeding, or sexually active with childbearing potential who is not using a medically accepted birth control method. 2. Participant has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study. 3. Participant has received any investigational drug or experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to study intervention administration. 4. Participant requires treatment with an anti-inflammatory drug during the study period. Paracetamol will be permitted for use as an antipyretic and/or analgesic (maximum of 4 grams/day in any 24 hour period). 5. Participant has an active infection (e.g. sepsis, pneumonia, abscess) or has had an infection requiring antibiotic treatment within 6 weeks prior to Investigational Medicinal Product (IMP) administration. When in doubt, the investigator should confer with the Sponsor study physician. 6. Participant has renal or liver impairment, defined as: 1. For healthy volunteers: i. For women, serum creatinine level = 125 µmol/L; for men, = 135 µmol/L, or ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 1.5 x upper limit of normal (ULN), or iii. Alkaline phosphatase (ALP) and/or bilirubin > 1.5 x ULN 2. For participants with mild to moderate atopic dermatitis or psoriasis: i. For women, serum creatinine level = 125 µmol/L; for men, = 135 µmol/L, or ii. ALT or AST > 2 x ULN and/or bilirubin > 1.5 x ULN

Study Design


Intervention

Drug:
EDP1815
EDP1815 is an orally administered monoclonal microbial
Placebo oral capsule
Placebo
Placebo oral tablet
Placebo

Locations

Country Name City State
United Kingdom UK-8 Barnsley
United Kingdom UK-7 Blackpool
United Kingdom UK-3 Cannock
United Kingdom UK-4 Leeds
United Kingdom UK-5 Liverpool
United Kingdom UK-1 London
United Kingdom UK-2 Manchester
United Kingdom UK-6 Manchester
United Kingdom UK-9 Stockton-on-Tees

Sponsors (1)

Lead Sponsor Collaborator
Evelo Biosciences, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability measured through Adverse Events (AEs) Number of participants with AEs by seriousness and relationship to treatment Day 1 to Day 70
Primary Safety and tolerability measured through lab measurements Number of participants with clinically significant change from baseline (Day 0) in laboratory values Day 0 to Day 70
Primary Safety and tolerability measured through ECG Number of participants with clinically relevant changes from baseline (Day 0) ECG parameters Day 0 to Day 70
Primary Safety and tolerability measured through physical examination Physical examination of stool samples based on the Bristol Stool Scale (Types 3 and 4 are ideal stool):
Type 1: Separate hard lumps, like nuts (hard to pass); Type 2: Sausage-shaped, but lumpy; Type 3: Like a sausage but with cracks on its surface; Type 4: Like a sausage or snake, smooth and soft; Type 5: Soft blobs with clear cut edges (easy to pass); Type 6: Fluffy pieces with ragged edges, a mushy stool; Type 7: Watery, no solid pieces, entirely liquid
Day 0 to Day 60
Primary GI safety measurement through biomarker analysis GI safety measurement through fecal calprotectin analysis Day 0 to Day 60
Secondary Clinical improvement in subjects with mild to moderate psoriasis Change from baseline (Day 0) Psoriasis-area-and-severity index score (PASI) in response to EDP1815, measured on a scale of 0 to 6 (where 0 is most favorable and 6 is least favorable). Day 0 to Day 70
Secondary Clinical improvement in subjects with mild to moderate atopic dermatitis Change from baseline (Day 0) Eczema-area-and-severity index score (EASI) in response to EDP1815, measured on a scale of 0 to 6 (where 0 is most favorable and 6 is least favorable). Day 0 to Day 70
See also
  Status Clinical Trial Phase
Completed NCT03236870 - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed NCT00078819 - Etanercept (Enbrel®) in Psoriasis - Pediatrics Phase 3
Completed NCT04841187 - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting NCT03927352 - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis Phase 3
Completed NCT03284879 - Post-Marketing Surveillance Study of OTEZLA
Recruiting NCT06027034 - Effectiveness of a Digital Health Application for Psoriasis N/A
Not yet recruiting NCT06050330 - CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study N/A
Recruiting NCT05744466 - A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Completed NCT04149587 - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed NCT01384630 - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis Phase 2
Completed NCT03998683 - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis Phase 3
Terminated NCT03556202 - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06077331 - A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT04316585 - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants Phase 1
Completed NCT04894890 - A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed NCT00358384 - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 Phase 1
Completed NCT03757013 - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Completed NCT05003531 - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 2